13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Gene expression‐based classifications of fibroadenomas and phyllodes tumours of the breast

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Fibroepithelial tumors (FTs) of the breast are a heterogeneous group of lesions ranging from fibroadenomas (FAD) to phyllodes tumors (PT) (benign, borderline, malignant). Further understanding of their molecular features and classification might be of clinical value. In this study, we analysed the expression of 105 breast cancer‐related genes, including the 50 genes of the PAM50 intrinsic subtype predictor and 12 genes of the Claudin‐low subtype predictor, in a panel of 75 FTs (34 FADs, 5 juvenile FADs, 20 benign PTs, 5 borderline PTs and 11 malignant PTs) with clinical follow‐up. In addition, we compared the expression profiles of FTs with those of 14 normal breast tissues and 49 primary invasive ductal carcinomas (IDCs). Our results revealed that the levels of expression of all breast cancer‐related genes can discriminate the various groups of FTs, together with normal breast tissues and IDCs (False Discovery Rate < 5%). Among FTs, the levels expression of proliferation‐related genes (e.g. CCNB1 and MKI67) and mesenchymal/epithelial‐related (e.g. CLDN3 and EPCAM) genes were found to be most discriminative. As expected, FADs showed the highest and lowest expression of epithelial‐ and proliferation‐related genes, respectively, whereas malignant PTs showed the opposite expression pattern. Interestingly, the overall profile of benign PTs was found more similar to FADs and normal breast tissues than the rest of tumours, including juvenile FADs. Within the dataset of IDCs and normal breast tissues, the vast majority of FADs, juvenile FADs, benign PTs and borderline PTs were identified as Normal‐like by intrinsic breast cancer subtyping, whereas 7 (63.6%) and 3 (27.3%) malignant PTs were identified as Claudin‐low and Basal‐like, respectively. Finally, we observed that the previously described PAM50 risk of relapse prognostic score better predicted outcome in FTs than the morphological classification, even within PTs‐only. Our results suggest that classification of FTs using gene expression‐based data is feasible and might provide clinically useful biological and prognostic information.

          Highlights

          • The levels expression of proliferation‐ and mesenchymal/epithelial‐related genes were found to be the most discriminative.

          • The overall profile of benign phyllodes was very similar to fibroadenomas.

          • The vast majority of fibroepithelial tumors (FTs) were identified as Normal‐like by the PAM50 and Claudin‐low predictors.

          • The PAM50 risk of relapse prognostic score better predicted outcome in FTs than the morphological classification.

          • Classification of FTs using gene expression‐based data provides clinically useful information.

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Cluster analysis and display of genome-wide expression patterns.

          A system of cluster analysis for genome-wide expression data from DNA microarray hybridization is described that uses standard statistical algorithms to arrange genes according to similarity in pattern of gene expression. The output is displayed graphically, conveying the clustering and the underlying expression data simultaneously in a form intuitive for biologists. We have found in the budding yeast Saccharomyces cerevisiae that clustering gene expression data groups together efficiently genes of known similar function, and we find a similar tendency in human data. Thus patterns seen in genome-wide expression experiments can be interpreted as indications of the status of cellular processes. Also, coexpression of genes of known function with poorly characterized or novel genes may provide a simple means of gaining leads to the functions of many genes for which information is not available currently.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Direct multiplexed measurement of gene expression with color-coded probe pairs.

            We describe a technology, the NanoString nCounter gene expression system, which captures and counts individual mRNA transcripts. Advantages over existing platforms include direct measurement of mRNA expression levels without enzymatic reactions or bias, sensitivity coupled with high multiplex capability, and digital readout. Experiments performed on 509 human genes yielded a replicate correlation coefficient of 0.999, a detection limit between 0.1 fM and 0.5 fM, and a linear dynamic range of over 500-fold. Comparison of the NanoString nCounter gene expression system with microarrays and TaqMan PCR demonstrated that the nCounter system is more sensitive than microarrays and similar in sensitivity to real-time PCR. Finally, a comparison of transcript levels for 21 genes across seven samples measured by the nCounter system and SYBR Green real-time PCR demonstrated similar patterns of gene expression at all transcript levels.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.

              To compare clinical, immunohistochemical (IHC), and gene expression models of prognosis applicable to formalin-fixed, paraffin-embedded blocks in a large series of estrogen receptor (ER)-positive breast cancers from patients uniformly treated with adjuvant tamoxifen. Quantitative real-time reverse transcription-PCR (qRT-PCR) assays for 50 genes identifying intrinsic breast cancer subtypes were completed on 786 specimens linked to clinical (median follow-up, 11.7 years) and IHC [ER, progesterone receptor (PR), HER2, and Ki67] data. Performance of predefined intrinsic subtype and risk-of-relapse scores was assessed using multivariable Cox models and Kaplan-Meier analysis. Harrell's C-index was used to compare fixed models trained in independent data sets, including proliferation signatures. Despite clinical ER positivity, 10% of cases were assigned to nonluminal subtypes. qRT-PCR signatures for proliferation genes gave more prognostic information than clinical assays for hormone receptors or Ki67. In Cox models incorporating standard prognostic variables, hazard ratios for breast cancer disease-specific survival over the first 5 years of follow-up, relative to the most common luminal A subtype, are 1.99 [95% confidence interval (CI), 1.09-3.64] for luminal B, 3.65 (95% CI, 1.64-8.16) for HER2-enriched subtype, and 17.71 (95% CI, 1.71-183.33) for the basal-like subtype. For node-negative disease, PAM50 qRT-PCR-based risk assignment weighted for tumor size and proliferation identifies a group with >95% 10-year survival without chemotherapy. In node-positive disease, PAM50-based prognostic models were also superior. The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points. ©2010 AACR.
                Bookmark

                Author and article information

                Contributors
                aprat@vhio.net
                Journal
                Mol Oncol
                Mol Oncol
                10.1002/(ISSN)1878-0261
                MOL2
                Molecular Oncology
                John Wiley and Sons Inc. (Hoboken )
                1574-7891
                1878-0261
                31 January 2015
                June 2015
                : 9
                : 6 ( doiID: 10.1002/mol2.2015.9.issue-6 )
                : 1081-1090
                Affiliations
                [ 1 ]Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain
                [ 2 ]Breast Cancer Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
                [ 3 ]Pathology Department, Vall d'Hebron University Hospital, Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain
                [ 4 ]Department of Medical Oncology, Lozano Blesa University Hospital, San Juan Bosco, 15, 50009, Zaragoza, Spain
                [ 5 ]Breast Cancer Surgical Oncology, Vall d'hebron Institute of Oncology (VHIO), Barcelona, Spain
                Author notes
                [*] [* ]Corresponding author. Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035, Barcelona, Spain.
                Article
                MOL22015961081
                10.1016/j.molonc.2015.01.003
                5528764
                25687451
                56f8e23d-e4e5-4c82-ae1d-899454239550
                © 2015 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 14 October 2014
                : 06 January 2015
                : 08 January 2015
                Page count
                Figures: 5, Tables: 3, Equations: 0, References: 40, Pages: 10, Words: 7251
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                mol22015961081
                June 2015
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.4 mode:remove_FC converted:25.07.2017

                Oncology & Radiotherapy
                fibroepithelial,fibroadenoma,juvenile fibroadenoma,phyllodes tumours,gene expression,intrinsic subtypes and claudin-low subtype

                Comments

                Comment on this article